A Randomized, Double Blind, Three-arm, Parallel Group, Single Dose Comparative PK, PD, Safety and Immunogenicity Study Comparing ADL-018 With US-licensed XOLAIR in Healthy Adult Subjects
Latest Information Update: 03 Feb 2025
At a glance
- Drugs Omalizumab (Primary)
- Indications Asthma
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Kashiv BioSciences
- 29 Jan 2025 Status changed from recruiting to completed.
- 15 Jun 2023 Planned End Date changed from 1 Mar 2023 to 15 Aug 2023.
- 15 Jun 2023 Planned primary completion date changed from 1 Feb 2023 to 30 Jul 2023.